CRUSADE Bleeding Risk Score Calculator

Clinical calculation support · Verify results before clinical use

Bleeding risk assessment

Enter baseline findings at presentation to estimate in-hospital major bleeding risk in NSTE-ACS.

—Score
Use the baseline hematocrit measured at presentation.
The original model specifies Cockcroft–Gault creatinine clearance, not laboratory eGFR.
Sex
Signs of heart failure at presentation
Diabetes mellitus
Prior vascular diseaseHistory of peripheral arterial disease or prior stroke.

About the CRUSADE Bleeding Score

The CRUSADE Bleeding Score estimates in-hospital major bleeding risk in patients presenting with non-ST-segment elevation myocardial infarction (NSTEMI). It uses eight baseline clinical variables and was derived and validated in a large multicenter registry.

Scoring criteria

VariableCriterionPoints
Hematocrit (%)<31 / 31–33.9 / 34–36.9 / 37–39.9 / ≥409 / 7 / 3 / 2 / 0
Creatinine clearance (mL/min)≤15 / >15–30 / >30–60 / >60–90 / >90–120 / >12039 / 35 / 28 / 17 / 7 / 0
Heart rate (beats/min)≤70 / 71–80 / 81–90 / 91–100 / 101–110 / 111–120 / ≥1210 / 1 / 3 / 6 / 8 / 10 / 11
Female sexFemale8
Heart failure signsPresent at presentation7
Prior vascular diseasePrior stroke or peripheral arterial disease6
Diabetes mellitusPresent6
Systolic blood pressure (mmHg)≤90 / 91–100 / 101–120 / 121–180 / 181–200 / ≥20110 / 8 / 5 / 1 / 3 / 5

Risk categories in the original cohort

Total scoreRisk groupIn-hospital major bleeding rate
1–20Very low3.1%
21–30Low5.5%
31–40Moderate8.6%
41–50High11.9%
>50Very high19.5%

These categories and rates reflect the original CRUSADE cohort and may not exactly represent contemporary local populations or an individual patient's risk.

References

Subherwal S, Bach RG, Chen AY, et al.Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE Bleeding Score. Circulation. 2009;119(14):1873–1882.DOI: 10.1161/CIRCULATIONAHA.108.828541PMID: 19332461

Clinical use and limitations

  • Developed for in-hospital major bleeding risk estimation in NSTEMI; applicability to other ACS populations should be considered carefully.
  • Creatinine clearance in the original model was estimated using Cockcroft–Gault. Do not substitute eGFR without considering the methodological difference.
  • The score is not a stand-alone treatment rule and should not delay indicated ACS care.
  • Use clinical judgement and current local guidelines when choosing antithrombotic therapy, dosing, invasive strategy, and monitoring.
Clinical disclaimer: This calculator is an educational and clinical decision-support aid, not a substitute for clinician judgement. Confirm input data and assess the complete clinical context, including ischemic risk, active bleeding, thrombocytopenia, anticoagulant use, renal function, and planned procedures. Do not use the CRUSADE score alone to withhold or delay indicated treatment.